UT-PROTEGRITY
18.11.2021 15:02:07 CET | Business Wire | Press release
Protegrity , a global leader in data security, today announced the availability of the Protegrity Data Protection Platform and Cloud Protect for Snowflake in the Microsoft Azure Marketplace, an online store providing applications and services for use on Microsoft Azure. Protegrity customers can now take advantage of the scalability, high availability, and security of Azure, with streamlined deployment and management.
Additionally, Protegrity has achieved Microsoft’s stringent Co-Sell Ready designation, unlocking the development of joint solutions, sales, and support through the Microsoft One Commercial Partner Program. Protegrity has also joined the Microsoft FastTrack certification program.
“Due to heightened sensitivity over data and privacy, many organizations have been slower to adopt cloud solutions,” said Jay Chitnis, vice president, global alliances and partners at Protegrity. “However, we’re now seeing a tipping point with businesses. Many of them want to make the most of the cloud to support AI and machine learning initiatives, so they can gain valuable insights from data, but they also recognize they have to safeguard the privacy of their customers, partners, and employees. That’s why it’s critical for organizations to secure data in any form and wherever it is—in the cloud or on premises—so it can be accessed across the enterprise by front-line employees, analytics teams, and anyone who needs data intelligence to make business decisions. Our collaboration with Microsoft ensures our mutual customers’ data is not at risk as it moves to the cloud, allowing organizations to accelerate cloud adoption.”
Jake Zborowski, general manager, Microsoft Azure Platform at Microsoft Corp., said, “We’re pleased to welcome Protegrity's solutions to the Microsoft Azure Marketplace, which gives our partners great exposure to cloud customers around the globe. Azure Marketplace offers world-class quality experiences from global trusted partners with solutions tested to work seamlessly with Azure.”
The Azure Marketplace is an online market for buying and selling cloud solutions certified to run on Azure. The Azure Marketplace helps connect companies seeking innovative, cloud-based solutions with partners who have developed solutions that are ready to use.
Seamless Data Protection to Support Advanced Analytics, AI, and Machine Learning on Microsoft Azure
As part of the Co-Sell Ready achievement, Protegrity met Microsoft’s strict architecture and security requirements. Protegrity will also continue to work with Microsoft account teams and partners to seamlessly deliver modern data protection and data privacy solutions to joint customers while supporting advanced analytics, AI, and machine learning, and Microsoft Azure cloud initiatives. Additionally, as part of the FastTrack program, Protegrity’s commitment to Microsoft Azure-based solutions will provide native security and performance for mutual customers.
Protegrity’s enterprise-class Data Protection Platform integration with Microsoft Azure enables customers to apply data-protection policies across different environments, entities, and jurisdictions. Additionally, customers are able to:
- Secure data moving to the cloud to reduce operational risk;
- Govern data in the cloud leveraging enterprise-wide information security policies; and
- Unlock and secure data analytics capabilities in the cloud.
Built for hybrid-cloud and multi-cloud, the Protegrity Data Protection Platform allows companies to seamlessly deploy and update data security policies across geographies, departments, and digital transformation programs. Businesses can quickly and safely turn sensitive data into intelligence-driven insights to deliver better customer experiences, monetize data responsibly, and support AI and machine learning initiatives.
Protegrity Data Protection Platform and Cloud Protect for Snowflake on Microsoft Azure Safeguard Sensitive Data for Privacy Compliance
Now available on the Microsoft Azure Marketplace, the Protegrity Data Protection Platform provides customers with fine-grained data protection capabilities for sensitive data and compliance. Protegrity accelerates analytics; minimizes risk in enterprise cloud adoption and migration; and meets storage, big data, and workload requirements. With its format-preserving vaultless tokenization capabilities and other forms of encryption, Protegrity safeguards data throughout every step of the data lifecycle.
Protegrity also announced the availability of Cloud Protect for Snowflake , which bundles two serverless components, the Snowflake Protector and Cloud API, to protect customers’ data and accelerate cloud migration and adoption of Snowflake.
- Snowflake Protector: The Snowflake Protector is a purpose-built protector that integrates seamlessly with Snowflake SQL to easily protect and unprotect sensitive data. Elastically scalable and benchmarked for high performance, the Protegrity Snowflake Protector enables organizations to support even the largest workloads.
- Cloud API: The Cloud API provides a general tokenization REST endpoint for use within ETL workflows. It can be used to protect data prior to ingestion into Snowflake, ensuring that data is always protected at rest.
With its support for Microsoft Azure, Protegrity continues to deliver on its commitment to expand cloud-inclusivity, enabling customers to maintain enterprise-wide data protection wherever sensitive data resides. Support for Microsoft points to one of many integrations Protegrity has with cloud providers as part of the new Protegrity Partner Network —a collaboration with leading technology companies that enables organizations to protect data in the cloud, regardless of vendor. With the freedom to safeguard data in any cloud system or application, organizations can unlock the potential of secure data no matter where it is and create more opportunities for innovation and digital transformation and improve customer experiences.
Learn more
Website: protegrity.com
Twitter: @Protegrity
LinkedIn: linkedin.com/company/protegrity
About Protegrity
Protegrity, a global leader in data security, protects sensitive data everywhere and future-proofs businesses as data-privacy regulations evolve. Maintaining privacy today across distributed data has become impossibly complicated. With Protegrity, enterprises can secure data wherever it resides, control how it’s protected, and have confidence that data is safe, even if a breach occurs. The Protegrity Data Protection Platform is a modern alternative to traditionally complex data-protection methods that leave gaps in security. Whether encrypting, tokenizing, or applying privacy models, Protegrity protects data at the speed of business. Deep integrations with Snowflake, Amazon Redshift, Teradata, Oracle, Microsoft SQL Server, Cloudera, Databricks, and many other enterprise applications ensure that data remains fully protected in hybrid-cloud, multi-cloud, and on-premises environments. The platform’s fine-grained data protection anonymizes personally identifiable information (PII) that’s used in AI and machine learning models, providing faster access to critical analytics data and dramatically shortening the time to business insights. Protegrity protects the sensitive data of more than two billion individuals across global enterprises, including four of the world’s 15 largest banks, four out of 10 of the top health insurance providers, and three of the world’s leading multinational companies. With more than two decades of industry-leading innovation, Protegrity allows businesses to finally tap into the value of their data and accelerate digital transformation timelines – without jeopardizing individuals’ fundamental right to privacy.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211118005259/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
